Hmg coa reductase inhibitors for promoting angiogenesis
CA 2411396 A1 · Owner: Walsh, Kenneth · Inventors: Walsh, Kenneth
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to methods and compositions for the treatment of conditions associated with vascular insufficiency and to methods and , compositions for screening assays to select agents that are useful for this purpose. In particular the invention relates to HMG CoA reductase inhibitors and their use in promoting angiogenesis in vivo and in activating Akt in vascular endothelial cells in vitro and in vivo.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 5, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 5, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 5, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.